Loading
Life sciences · Journal article
Diabetes Obesity and Metabolism · October 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Key Messages GLP‐1 receptor agonists and metabolic bariatric surgery are complementary tools in chronic obesity care, not simple substitutes. Trial efficacy, real‐world effectiveness, durability, affordability, indirect costs and implementation capacity need separate assessment. Surgery can produce durable weight loss and cardiometabolic benefit in selected patients, but requires operative capacity, multidisciplinary preparation, recovery time and lifelong nutritional and metabolic follow‐up. Incretin‐based pharmacotherapy has transformed obesity treatment, but real‐world persistence, price, supply and clinical support remain central determinants of value. Effective obesity pharmacotherapy usually requires long‐term continuation to sustain clinical benefit; inadequate response or treatment discontinuation should prompt an individualised transition plan rather than passive observation. Policy should be tailored to local disease burden, primary‐care capacity, surgical services, medicines access, financing and equity constraints.